Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 393 matching trials from the live ClinicalTrials.gov search.
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0913
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Completed No phase listed Observational Results available

PRESERFLO® MicroShunt Extension Study

NCT04333433
Conditions
Primary Open-angle Glaucoma
Interventions
PRESERFLO® MicroShunt, Trabeculectomy
Device · Procedure
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
279 participants
Timeline
2020 – 2022
U.S. locations
19
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Los Angeles, California + 16 more
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Massachusetts
Conditions
Ocular Surface Disease, Glaucoma, Open-Angle
Interventions
iStent or iStent inject implantation with concomitant cataract surgery
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Conditions
Open Angle Glaucoma
Interventions
Micropulse Laser Trabeculoplasty, Selective Laser Trabeculoplasty
Device
Lead sponsor
David Belyea
Other
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Glaucoma Drug Delivery System

NCT00824720
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
High Dose Device, Low Dose Device, Placebo Device
Drug · Device
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more
Not listed No phase listed Observational Accepts healthy volunteers

African Descent and Glaucoma Evaluation Study

NCT00221923
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • La Jolla, California • New York, New York
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
Interventions
ALZ-1101, Latanoprost
Drug
Lead sponsor
Alleanza Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Morrow, Georgia
Conditions
Open Angle Glaucoma
Interventions
Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
Device
Lead sponsor
Diablo Eye Associates
Industry
Eligibility
60 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Walnut Creek, California
Conditions
Glaucoma, Glaucoma, Open-Angle
Interventions
Hydrus Microstent, Incisional goniotomy, Excisional goniotomy
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Primary Open Angle Glaucoma, Low Tension Glaucoma, Cataract, Ocular Hypertension
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Primary Open Angle Glaucoma, Cataract
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more
Conditions
Glaucoma, Open-Angle, Cataract
Interventions
Vivity IOL
Device
Lead sponsor
Vold Vision P.L.L.C
Other
Eligibility
45 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Fayetteville, Arkansas
Conditions
Ocular Hypertension, Glaucoma
Interventions
AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Artesia, California
Conditions
Glaucoma
Interventions
endoscopic goniotomy
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Week to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
Drug · Procedure
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
51
States / cities
Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Caffeinated Coffee on Intraocular Pressure

NCT01364207
Conditions
Primary Open Angle Glaucoma
Interventions
Caffeinated Coffee, Decaffeinated Coffee
Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Open Angle Glaucoma
Interventions
OMNI Surgical System
Device
Lead sponsor
Mark Gallardo, MD
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
El Paso, Texas
Completed No phase listed Observational Accepts healthy volunteers

Absorption and Safety of Topical Timolol to Treat Chronic Wounds

NCT04903366
Conditions
Glaucoma, Open-Angle, Chronic Wounds
Interventions
Timolol Maleate
Drug
Lead sponsor
VA Northern California Health Care System
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mather, California
Conditions
Glaucoma, Open Angle Glaucoma, Ocular Hypertension
Interventions
PhXA41, timolol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1994
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Gainesville, Florida + 12 more
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
JV-GL1, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
JeniVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama